Draft of USP Chapter <711> Dissolution (PDG harmonized document) Published for Comments
Recommendation
Tuesday, 14 January 2025 13.00 - 17.30 h
In the Pharmacopeial Forum, PF 49(3), a proposal of a revised USP General Chapter <711> Dissolution has been published for comments. The background to the publication is the efforts of international harmonization of monographs and general analytical methods of the European, Japanese, and United States pharmacopeias.
The Pharmacopoeial Discussion Group (PDG)
The Pharmacopoeial Discussion Group (PDG), which was created in 1989, brings together
- the Japanese Pharmacopoeia (JP),
- the European Pharmacopoeia (Ph. Eur.),
- and the United States Pharmacopeia (USP).
The PDG works on pharmacopoeial harmonization of excipient monographs and general chapters.
Revised USP Chapter <711> Dissolution
The now published proposal is based on the version of the USP chapter official since 01 May 2023. It represents the official inquiry stage 2A of Revision 5 to the PDG harmonized document.
According to the briefing notes, the draft includes changes in the following sections:
- "Apparatus, Apparatus 1 (basket apparatus)
- Apparatus 3 (Reciprocating Cylinder)
- Apparatus 4 (Flow-Through Cell)
- Apparatus 4 (Flow-Through Cell), Apparatus Suitability
- Procedure, Apparatus 1 and Apparatus 2, Immediate-Release Dosage Forms
- Procedure, Apparatus 1 and Apparatus 2, Delayed-Release Dosage Forms
- Procedure, Apparatus 3 (reciprocating cylinder), Immediate-Release Dosage Forms, Extended-Release Dosage Forms, and Delayed-Release Dosage Forms
- Procedure, Apparatus 4 (Flow-through Cell), Immediate-Release Dosage Forms, Extended-Release Dosage Forms, and Delayed-Release Dosage Forms
- Interpretation, Immediate-Release Dosage Forms, Acceptance Table 1
- Interpretation, Extended-Release Dosage Forms, Acceptance Table 2
- Interpretation, Delayed-Release Dosage Forms, Acid Stage, Acceptance Table 3, and Buffer Stage, Acceptance Table 4"
The draft of the revised chapter is available on PF Online. The comment period is open from now on until 31 July 2023.
Related GMP News
11.12.2024Another FDA Warning Letter Based on Review of Records
04.12.2024FDA Warning Letter to South African OTC Drug Manufacturer
02.12.2024How to keep Analytical Systems Current and Compliant
27.11.2024FDA Inspections in the EU: Warning Letter to Italian OTC Drug Manufacturer
21.11.2024New GMP Journal Article on Analytical Instrument Qualification and System Validation
21.11.2024FDA Warns Chinese OTC Drug Manufacturer Following Review of Records